Anavex Life Sciences Corp AVXL

Morningstar Rating

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

AVXL is trading at a LOCK|^#<PM premium.
Price
$1.89
Fair Value
LOCK|t!?P%j
Uncertainty
LOCK|$S $^wN
1-Star Price
LOCK|Q<JH#h
5-Star Price
LOCK|&hCv#T
Economic Moat
LOCK|V^L
Capital Allocation
—

News

Trading Information

Previous Close Price
—
Day Range
—–—
52-Week Range
—–—
Bid/Ask
— / —
Shares Outstanding
92.70M
Market Cap
—
Volume/Avg
— / —

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
—
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
34

Valuation

Metric
AVXL
Price/Earnings (Normalized)
—
Price/Book Value
1.56
Price/Sales
—
Price/Cash Flow
—
Price/Earnings
No chart available

Financial Strength

Metric
AVXL
Quick Ratio
15.51
Current Ratio
15.62
Interest Coverage
—
Quick Ratio
AVXL

Profitability

Metric
AVXL
Return on Assets (Normalized)
−21.22%
Return on Equity (Normalized)
−22.84%
Return on Invested Capital (Normalized)
−26.69%
Return on Assets
AVXL

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|><#QT&LOCK|&?gc$128B
Regeneron Pharmaceuticals Inc
REGN
LOCK|?F$pfdLOCK|b&MW$76B
Moderna Inc
MRNA
LOCK|@Y$@!@LOCK|X<$75B
argenx SE ADR
ARGX
LOCK|>^R!y<LOCK|b<$60B
BeOne Medicines Ltd ADR
ONC
LOCK|?h#jDT#LOCK|!cg$44B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|?PM%d#zLOCK|>HH<!$31B
Royalty Pharma PLC Class A
RPRX
LOCK|K>bmmkt@LOCK|@Q>^$26B
BioNTech SE ADR
BNTX
LOCK|&wzxCqLOCK|Pm?$24B
Incyte Corp
INCY
LOCK|$j$f#^LOCK|#&$24B
Jazz Pharmaceuticals PLC
JAZZ
LOCK|@?C$<fLOCK|dn$15B

Sponsor Center